The bank maintained its buy rating and lifted its price target on Nvidia heading into the chipmaker’s next earnings release, slated for Nov. 19.
Cloud revenue is sending Amazon shares soaring. Here’s what analysts had to say
Cloud growth has been a widely watched metric for the company as rivals such as Google and Microsoft ramp up the pressure.
Apple’s latest earnings came in hot thanks to the iPhone 17. Here’s how analysts are reacting
For the most part, Apple’s fiscal fourth-quarter results has analysts thinking the stock is primed for more gains going forward.
Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
The clinical-stage biopharma stock has rallied more than 70% over the past three months on the back of promising clinical data for its lead drug, Palazestrant.
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Rigel Pharmaceuticals has landed on CNBC’s list of top performing stocks of companies located in San Francisco.
History shows these companies reporting earnings next week tend to beat expectations
Wingstop, Arista Networks and Shopify are among the stocks that could beat expectations next week and then see a post-earnings rise in their shares.
Food inflation is killing Chipotle. Wall Street sees little way out for company if it doesn’t raise prices
Analysts are zeroing in on the potential impact of food inflation to margins and earnings.
Apple’s September quarter earnings are coming after Thursday’s market close. Here’s what top analysts expect
Some Wall Street price targets suggest Apple shares could rise as much as about 20% from here.
Tariffs were supposed to kill these two stocks. Instead, they are the most surprising winners of the year
Some of the year’s biggest winners have been the obvious trades like Nvidia and Broadcom. And some have been completely out of left field.
This stock was once one of the riskiest on Wall Street. Now it has a strong balance sheet and is cheap
This stock is re-emerging as a modest-growth story at a cheap valuation, with a very strong balance sheet.